Subclinical thyroid disorders: The menace of the Trojan horse

Journal of Endocrinological Investigation

Volumn 26, Issue 5, 2003, Pages 472-480

  Duntas, Leonidas H ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Disorders; Subclinical thyroid; Thyroid

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA INTERFERON; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIDEPRESSANT AGENT; ANTITHYROID AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; DICLOFENAC; DOMPERIDONE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; ESTROGEN; FUROSEMIDE; GLUCOCORTICOID; IODINE DERIVATIVE; LEVOTHYROXINE; LIPID; LITHIUM SALT; METOCLOPRAMIDE; RADIOACTIVE IODINE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN; THYROID ANTIBODY; THYROID HORMONE; THYROTROPIN;

ATHEROSCLEROSIS; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE CALCULATION; DRUG MONITORING; DRUG OVERDOSE; DYSLIPIDEMIA; ELDERLY CARE; EXERCISE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONTRACTILITY; HIGH RISK POPULATION; HORMONE DETERMINATION; HUMAN; LABORATORY TEST; MORBIDITY; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PREVALENCE; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; SUBCLINICAL HYPERTHYROIDISM; SUBCLINICAL HYPOTHYROIDISM; SUBCLINICAL THYROID DISEASE; THYROID DISEASE; THYROID FAILURE; THYROID HORMONE SYNTHESIS; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TREATMENT PLANNING;

EID: 0042813706     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345205     Document Type: Review

References (88)

1. Evered D., Hall R. Hypothyroidism. B.M.J. 1972, 1: 290-293.
2. Gemsenjäger E., Staub J.J., Girard J., Heitz P.H. Preclinical hyperthyroidism in multinodular goiter. J. Clin. Endocrinol. Metab. 1976, 43: 810-816.
3. Evered D.C., Ormston B.J., Smith P.A., Hall R., Bird T. Grades of hypothyroidism. B.M.J. 1973, 1: 657-662.
4. Ayala A.R., Wartofsky L. The case for more aggressive screening and treatment of mild thyroid failure. Cleve. Clin. J. Med. 2002, 4: 313-320.
5. Wilansky D.L., Greisman B. Early hypothyroidism in patients with menorrhagia. Am. J. Obstet. Gynecol. 1989, 160: 673-677.
6. Duntas L.H. Subclinical hypothyroidism: A misnomer in search of a new name. Thyroid 2001, 11: 361-362.
7. Lauberg P., Bulow-Pedersen I., Knudsen N., Oversen L., Andersen S. Environmental iodine intake affects the type of non-malignant thyroid disease. Thyroid 2001, 11: 457-469.
8. Vanderpump M.P.J., Tunbridge W.M.G., French J.M., et al. The incidence of thyroid disorders in the community: A twenty-year follow-up of the Whickham Survey. Clin. Endocrinol. (Oxf.) 1995, 43: 55-68
9. Sawin C.T., Geller A., Kaplan M.M., Bacharach P., Wilson P.W.F., Hershman J.M. Low serum thyrotropin (Thyroid-Stimulating-Hormone) in older persons without hyperthyroidism. Arch. Intern. Med. 1991, 151: 165-168.
10. Canaris G.J., Manowitz N.R., Mayor G., Ridgway E.C. The Colorado thyroid disease prevalence study. Arch. Intern. Med. 2000, 160: 526-534.
11. Hollowell J.C., Staehling N.W., Hannon W.H., et al. Serum thyrotropin, thyroxine, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J. Clin. Endocrinol. Metab. 2002, 87: 489-499.
12. Bartalena L., Martino F., Velluzzi M., et al. The lack of nocturnal serum thyrotropin surge in patients with nontoxic nodular goiter may predict the subsequent occurrence of hyperthyroidism. J. Clin. Endocrinol. Metab. 1991, 73: 604-608.
13. Spencer C.A., Schwarzbein D., Guttler R.B., LoPresti J.S., Nicoloff J.T. Thyrotropin (TSH)-releasing hormone stimulation test responses employing third and fourth generation TSH assays. J. Clin. Endocrinol. Metab. 1993, 76: 494-498.
14. Fatourechi V. Adverse effects of subclinical hyperthyroidism. Lancet 2001, 358: 856-857.
15. Subclinical hyperthyroidism: Position statement from the American Association of Clinical Endocrinologists. Endocrine Practice 1999, 5: 220-221.
16. Braverman L.E., Pearce E.N. Subclinical hyperthyroidism Thyroid International 2001, 5: 3-11.
17. Parle J.V., Franklyn J.A., Cross K.W., Jones S.C., Sheppard M.C. Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. Clin. Endocrinol. (Oxf.) 1991, 34: 77-83.
18. Schlote-Sautter B., Schmidt R., Kaumeier S., Teuber J., Vardarli I., Usaldel K.H. Subclinical hyperthyroidism: Do physical and mental symptoms exist that justify treatment? In: Reinwein D. and Scriba P.C. (Eds.), The Various Types of Hyperthyroidism. Urban & Schwartzenberg, Munich, 1990, p. 319.
19. Muente T.F., Radamm C., Soenke J., Brabant G. Alererations of cognitive functions induced by exogenous application of thyroid hormones in healthy men: A double-blind cross-over study using event-related brain potentials. Thyroid 2001, 11: 385-391.
20. Eriksen E.F. Normal and pathological remodelling of human trabecular bone: Three dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease. Endocr. Rev. 1986, 7: 379-408.
21. Ross D.S. Subclinical hyperthyroidism. In: Braverman L.E., Utiger R.D. (Eds.), Werner and Ingbar's The Thyroid, ed. 6. J.B. Lippincott Company, Philadelphia, 1991, p. 1249.
22. Ross D.S., Neer R.M., Ridgway R.C., Daniels G.H. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with I-thyroxine. Am. J. Med. 1987, 82: 1167-1170.
23. Grant D.J., McMurdo M.E.T., Mole P.A., Paterson C.R., Davies R.R. Suppressed TSH levels secondary to thyroxine replacement therapy are not associated with osteoporosis. Clin. Endocrinol. (Oxf.) 1993, 39: 529-533.
24. Faber, J., Galloe A.M. Changes in bone mass during prolonged subclinical hyperthyroidism due to I-thyroxine treatment: A meta-analysis. Eur. J. Endocrinol. 1994, 130: 350-356.
25. Marcocci C., Golia F., Vignali E., Pinchera A. Skeletal integrity in men chronically treated with suppressive doses of I-thyroxine. J. Bone Min. Res. 1997, 12: 72-77.
26. Gurlek K.A., Cedik O. Effect of endogenous subclinical hyperthyroidism on bone metabolism and bone mineral density in premenopausal women. Thyroid 1999, 9: 539-543.
27. Faber J., Jensen I.W., Petersen L., Nygaard B., Hegedus L., Siersbaek N.K. Normalization of serum thyrotropin by means of radiodine treatment in subclinical hyperthyroidism: Effect on bone loss in postmenopausal women. Clin. Endocrinol. (Oxf.) 1998, 48: 285-290.
28. Guo C.Y., Weetman A.P., Eastell R. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clin. Endocrinol. (Oxf.) 1997, 46: 301-307.
29. Uzzan B., Campos J., Cucherat M., Nony P., Boissel J.P., Perret G.Y. Effects on bone mass of long term treatment with thyroid hormones: A meta-analysis. J. Clin. Endocrinol. Metab. 1996, 81: 4278-4289.
30. Bauer D.C., Ettinger B., Nevitt M.C., Stone K.L. Risk for fracture in women with low serum levels of thyroid-stimulating hormone. Ann. Intern. Med. 2001, 134: 561-568.
31. Klein I. Thyroid hormone and the cardiovascular system. Am. J. Med. 1990, 88: 631-637.
32. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001, 7: 501-509
33. Mercuro G., Panzuto M.G., Bina A., et al. Cardiac function, physical exercise capacity, and quality of life during long-term thyrotropin-suppressive therapy with levothyroxine: Effect of individual dose tailoring. J. Clin. Endocrinol. Metab. 2000, 85: 159-164.
34. Biondi B., Palmieri E.A., Fazio S., et al. Endogenous subclinical hyperthyroidism affects quality of life, cardiac morphology and function in young and middle-aged patients. J. Clin. Endocrinol. Metab. 2000, 12: 4701-4705.
35. Sawin C.T., Geller A., Wolf P.A., et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N. Engl. J. Med. 1994, 331: 1249-1252.
36. Auer J., Scheibner P., Mische T., Langsteger W., Eber O., Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am. Heart J. 2001, 142: 838-842.
37. Ladenson P.W. Thyrotoxicosis and the heart: Old and something new. J. Clin. Endocrinol. Metab. 1993, 77: 332-333.
38. Kalmijn S., Mehta K.M., Pols H.A.P., Hofman A., Drexhage H.A., Breteler M.M.B. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study. Clin. Endocrinol. (Oxf.) 2000, 53: 733-737.
39. Parle J.V., Maisonneuve P., Sheppard MC., Boyle P., Franklyn J.A. Prediction of all cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: A 10 year cohort study. Lancet 2001, 385: 861-865.
40. Shrier D.K., Burman K.D. Subclinical hyperthyroidism: Controversies in management. Am. Fam. Physician 2002, 3: 431-438.
41. Levy E.G. (section editor). Subclinical hyperthyroidism. Thyroid 2000, 10: 721-723.
42. Sawin C.T. Subclinical hyperthyroidism and atrial fibrillation. Thyroid 2002, 6: 501-503.
43. Tunbridge W.M., Evered D.C., Hall R., et al. Lipid profiles and cardiovascular disease in the Wickham area with particular reference to thyroid failure. Clin. Endocrinol. (Oxf.) 1977, 7: 495-508.
44. Sawin C.T., Castelli W.P., Hershman J.M., Mc Namara P., Bacharach P. The aging thyroid: Thyroid deficiency in the Framingham Study. Arch. Intern. Med. 1985, 145: 1386-1388.
45. Duntas L.H. Recap of the clinical use of thyrotropin-releasing hormone. In: Duntas L.H. and Guillemin R. (Eds.), Hypothalamic Releasing Hormones. Challenges and Perspective at the 2000 Year Mark. Beta Medical Arts, Athens, 2000, p. 31.
46. Faglia G. The clinical impact of thyrotropin-releasing hormone test. Thyroid 1998, 10: 903-908.
47. Michalakopoulou G., Alevizaki M., Piperingos G., et al. High serum cholesterol levels in persons with "high-normal" TSH levels: Should one extend the definition of subclinical hypothyroidism? Eur. J. Endocrinol. 1998, 138: 141-145.
48. Lekakis J., Papamichael C., Alevizaki M., et al. Flow-mediated endothelium dependent vasodilation is impaired in subjects with hypothyroidism, borderline hypothyroidism and high-normal serum thyrotropin (TSH) values. Thyroid 1997, 7: 411-414.
49. Cooper D.S. Subclinical hypothyroism. N. Engl. J. Med. 2001, 345: 260-265.
50. Ladenson P.W., Singer P.A., Ain K.B., et al. American Thyroid Association guidelines for detection of thyroid dysfunction. Arch. Intern. Med. 2000, 160: 1573-1575.
51. Danese M.D., Powe N.R., Sawin C.T., Ladenson P.W. Screening for mild thyroid failure at the periodic health examination: A decision and cost-effectiveness analysis. J.A.M.A. 1996, 276: 285-292.
52. Haddow J.E., Palomaki G.E., Allan W.C., et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsycho-logical development of the child. N. Engl. J. Med. 1999, 341: 549-555.
53. Klein R.Z., Sargent J.D., Larsen P.R., Waisbren S.E., Haddow J.E., Mitchell M.L. Relation to severity of maternal hypothyroidism to cognitive development of offspring. J. Med. Screen. 2001, 1: 18-20.
54. Davies P.H., Franklyn J.A. The effect of drugs on tests of thyroid function. Eur. J. Clin. Pharmacol. 1991, 40: 439-451.
55. Asher R. Myxedematous madness. B.M.J. 1949, 22: 555-562.
56. Nemeroff C.B. Subclinical hypothyroidism: A review of neuropsychiatric aspects. Int. J. Psychiatry Med. 1990, 20: 193-208.
57. Haggerty JJ., Stern R.A., Mason G.A., Beckwith J., Morey C.E., Prange A.J. Jr. Prevalence of antithyroid antibodies in mood disorders. Am. J. Psychiatry 1993, 3: 508-510.
58. Berlin I., Payan C., Corruble E., Puech A.J. Serum thyroid-stimulating-hormone concentration as an index of severity of major depression. Int. J. Neurospsychopharmacol. 1999, 2: 105-110.
59. Nystroem E., Caidahl K., Fager G., Wikkelso C., Lundberg P.A., Lindstedt G. A double-blind cross-over 12-month study of I-thyroxine treatment of women with 'subclinical hypothyroidism'. Clin. Endocrinol. (Oxf.) 1988, 1: 63-75.
60. Monzani F., Caraccio N., Siciliano G., Manca L., Murri L., Ferannini E. Clinical and biochemical features of muscle dysfunction in subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 1997, 82: 3315-3318.
61. Goulis D.G., Tsimpiris N., Delaroudis S., et al. Stapedial reflex: A biologic index found to be abnormal in clinical and subclinical hypothyroidism. Thyroid 1998, 8: 583-587
62. Duntas L.H., Papanastasiou L., Mantzou E., Koutras D.A. Incidence of sideropenia and effects of iron repletion treatment in women with subclinical hypothyroidism. Exp. Clin. Endocrinol. Diabetes 1999, 107: 356-360.
63. Tagliaferri M., Berselli M.E., Calo G., et al. Subclinical hypothyroidism in obese patients: Relation to resting energy expenditure, serum leptin, body composition and lipid profile. Obes. Res. 2001, 9: 196-201.
64. Benvenga S., Robbins S. Lipoprotein-thyroid hormone interactions. Trends Endocrinol. Metab. 1996, 4: 194-198.
65. Duntas L. Thyroid disease and lipids. Thyroid 2002, 12: 287-293.
66. Tan K.C.B., Shiu S.W.M., Kung A.W.C. Plasma cholesteryl ester transfer protein activity in hyper-and hypothyroidism. J. Clin. Endocrinol. Metab. 1998; 83: 149-153.
67. Althaus B.U., Staub J.J., Ryff-de Leche A., Oberhaenslie A., Staehelin H.B. LDL/HDL changes in subclinical hypothyroidism: Possible risk factors for coronary heart disease. Clin. Edocrinol. (Oxf.) 1988, 28: 157-163.
68. Bindels A.J.G.H., Westerndorp R.G.J., Froehlich M., Seidell J.C., Blokstra A., Smelt A.H.M. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: A need for case-finding. Clin. Endocrinol. (Oxf.) 1999, 50: 217-220.
69. Bakker S.J.L., Ter Maaten J.C., Popp-Snijders C., Slaets J.P.J., Heine R.J., Gans R.O.B. The relationship between thyrotropin and low-density lipoprotein cholesterol is modified by insulin sensitivity in healthy euthyroid subjects. J. Clin. Endocrinol. Metab. 2001, 86: 1206-1211.
70. Vanderpump M.P., Tunbridge W.M., French J.M., et al. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of English community. Thyroid 1996, 6: 155-160.
71. Hak E.A., Huibert A.P., Visser T.J., Drexhage H.A., Hofman A. Witterman J.C.M. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: The Rotterdam study. Ann. Intern. Med. 2000, 132: 270-278.
72. Huber G. Staub J.J. Meier C. et al. Prospective study of the spontaneous course of subclinical hypothyroidism: Prognostic value of thyrotropin, thyroid reserve, and thyroid antibodies. J. Cli. Endocriol. Metab. 2002, 87: 3221-3226.
73. Meier C., Staub J.J., Roth C.B., et al. TSH-controlled-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: A double blind, placebo-controlled trial (Basel Thyroid Study). J. Clin. Endocrinol. Metab. 2001, 86: 4860-4866.
74. Danese M.D., Ladenson P.W., Meinert C.L., Powe N.R. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: A quantitative review of the literature. J. Clin. Endocrinol. Metab. 2000, 85: 2993-3001.
75. Tanis B.C., Westerdorp G.J., Smelt H.M. Effect of thyroid substitution of hypercholesterolemia in patients with subclinical hypothyroidism: A reanalysis of intervention studies. Clin. Endocrinol. (Oxf.) 19996 44: 643-649.
76. Alvarez J.J, Lasuncion M.A, Olmos J.M, Herrera E. Interindividual variation in the partition of lipoprotein (a) into lipoprotein subfractions. Clin. Biochem. 1993, 26: 399-408.
77. Pazos F., Alvarez J.J., Rubies-Prat J., Varela C., Lasuncion M.A. Long term thyroid hormone replacement therapy and levels of lipoprotein and other lipoproteins. J. Clin. Endocrinol. Metab. 80: 562-566.
78. Danzi S., Klein I. Thyroid hormone-regulated cardia gene expression and cardiovascular disease. Thyroid 2002, 12: 467-472.
79. Kahaly G.J. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid 2000, 10: 665-679
80. Arem R., Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch. Intern. Med. 1990, 150: 2097-2100.
81. Biondi B., Fazio S., Palmieri E.A., et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J. Clin. Endocrinol. Metab. 1999, 84: 2064-2067.
82. Foeldes J., Istvanfy M., Halmagyi M., Varadi A., Gara A, Partos O. Hypothyroidism and the heart examination of left ventricular function in subclinical hypothyroidism. Acta. Med Hung. 1987, 44: 337-347.
83. Biondi B., Palmeri E.A., Lombardi G., Fazio S. Subclinical hypothyroidism and cardiac function. Thyroid 2002, 12: 505-510.
84. Cooper D.S., Halpern R., Wood L.C., Levin A.A., Ridgway E.C. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann. Intern. Med. 1984, 101: 18-24.
85. Faber J., Petersen L., Winberg N., Shifter S., Mehlsen J. Hemodynamic changes after levothyroxine treatment in subclinical hypothyroidism. Thyroid 2002, 10: 319-324.
86. Chu J.W., Crapo L.M. The treatment of subclinical hypothyroidism in seldom necessary. J. Clin. Endocrinol. Metab. 2001, 86: 4591-4599.
87. Zulewski H., Mueller B., Exer P., Miserez A., Staub J.J. Estimation of tissue hypothyroidism by a new clinical score: Evaluation of patients with various grades of hypothyroidism and controls. J. Clin. Endocrinol. Metab. 1997, 82: 771-776.
88. Andersen S., Pedersen K.M., Brunn N.H., Laurberg P. Narrow individual variations in serum T(4) and T(3) in normal subjects: A clue to the understanding of subclinical thyroid disease. J. Clin. Endocrinol. Metab. 2002, 87: 1068-1072.